- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01255280
Behavioral Activation and HIV Risk Reduction for Men Who Have Sex With Men With Crystal Meth Abuse
May 31, 2012 updated by: Matthew James Mimiaga, Massachusetts General Hospital
Behavioral Activation and HIV Risk Reduction for MSM With Crystal Methamphetamine Abuse
The purpose of this study is to research a new behavioral treatment to reduce sexual risk-taking in men who have sex with men (MSM) who abuse crystal methamphetamine (crystal meth), and are at risk for HIV acquisition.
This study proposes using a treatment based on our original pilot study that incorporates risk reduction and behavioral activation therapy.
In order to help learn what types of treatment programs best help individuals who abuse crystal meth and engage in sexual risk-taking, we will compare our treatment to a control group.
The treatment group will receive therapy incorporating behavioral risk reduction counseling with behavioral activation therapy to treat depression, helping individuals reengage in their life.
The control group will receive the risk reduction counseling without the behavioral activation therapy.
The current study hopes to explore the efficacy of this previous developed treatment in a two-arm pilot randomized controlled trial.
Study Overview
Status
Unknown
Detailed Description
- To estimate, in a two-arm pilot randomized controlled trial (RCT), the effect size of the proposed intervention on reductions in sexual risk taking and crystal meth use. The primary outcome is the number of unprotected anal sex acts and a secondary outcome is reduction in crystal meth use episodes over the follow up period.
- To explore the degree to which improvements in sexual risk taking are associated with the conceptual mediators of the effects of the intervention: reductions in crystal meth use and increases in pleasurable (but safe) activities, BAT skills, use of risk reduction skills, and reductions in depressed mood.
Study Type
Interventional
Enrollment (Anticipated)
50
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02215
- Recruiting
- Fenway Community Health
-
Contact:
- Jaclyn White, MPH
- Phone Number: 617-927-6101
- Email: jwhite@fenwayhealth.org
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
14 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
Male
Description
Inclusion Criteria:
- Age: 18 years or older
- Self-reports as a man who has sex with men
- HIV-uninfected and verifies serostatus at baseline (HIV antibody testing and positive tests will be confirmed by Western Blots; see Human Subjects for operational aspects)
- Meets DSM-IV diagnostic criteria for crystal meth abuse/dependence
- Self reported unprotected anal intercourse-receptive or insertive-with a non-monogamous male sexual partner, while concurrently using crystal meth (use of meth must be a few hours prior to, or during, sex) in the prior three months
Exclusion Criteria:
- Unable to provide informed consent due to severe mental or physical illness, or substance intoxication at the time of interview
- Has lived in the greater Boston area for three months or less (as a means to enhance participant retention)
- Discovery of active suicidal ideation at the time of interview (these patients will be referred immediately for treatment, but may join the study when this is resolved)
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Active Comparator: Information, Motivation, Behavioral skills
The comparison condition will only receive the two IMB risk reduction sessions.
The intervention will begin with modules that focus directly with sexual risk reduction practices.
It will begin with a discussion of one's sexual history, sexual risk limits, and barriers (e.g., motivation or skills) to staying in their sexual risk limits.
This session will also involve a Q&A discussion and the use of a fact sheet regarding HIV acquisition risk behaviors (information).
The next session will involve motivational interviewing and the formulation of an individualized behavioral skills plan as needed.
|
The comparison condition will only receive the two IMB risk reduction sessions.
|
|
Experimental: Behavioral Activation Therapy and Risk Reduction Counseling
This intervention is given to patients in the experimental condition only and is comprised of 10 sessions-1 baseline session focused on orienting and rationale, 2 focused on risk reduction (consistent with the IMB model: information, motivation, and behavioral skills), 6 incorporating behavioral activation therapy/risk reduction counseling, and 1 final session on relapse prevention.
Each session will last approximately fifty minutes in length; and will also involve a review of the previous materials,and hence the behavioral activation approach will be woven back into the risk reduction content.
|
This intervention is given to patients in the experimental condition only and is comprised of 10 sessions.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in sexual risk
Time Frame: Baseline and three months post-treatment; baseline and six months post-treatment
|
We will ask about number of unprotected and protected insertive and receptive anal, vaginal and oral sex acts with male and female sex partners separately for HIV seropositive, seronegative, and partners of unknown HIV status with questions from measures used in previous studies.
We will use this to calculate the ratio of protected to unprotected acts, by serostatus partner, and by whether or not crystal meth was being used before or during sex.
Baseline and three and six-month follow-up assessments will assess sexual risk taking in the previous 3-months to the assessment being completed.
|
Baseline and three months post-treatment; baseline and six months post-treatment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in crystal methamphetamine use
Time Frame: Baseline and three months post-treatment; baseline and six months post-treatment
|
For the present study, we will administer relevant sections of the Drug and Alcohol sections of the NIDA-CTN Addictions Severity Index Lite (ASI-Lite).
We will use this methodology to determine the number of days of drug use, specifically crystal meth, and the number of distinct crystal meth episodes between study assessment visits (i.e., separate crystal meth binges).In addition to the ASI-Lite, we will also collect participant self-report measures of substance use via the ACASI.
We have adapted and will also use the CDC's National HIV Behavioral Surveillance Survey, MSM cycle.
|
Baseline and three months post-treatment; baseline and six months post-treatment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Collaborators
Investigators
- Principal Investigator: Matthew Mimiaga, ScD, Fenway Community Health and Massachusetts General Hospital/Harvard Medical School
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
January 1, 2011
Primary Completion (Anticipated)
December 1, 2013
Study Completion (Anticipated)
December 1, 2013
Study Registration Dates
First Submitted
December 3, 2010
First Submitted That Met QC Criteria
December 6, 2010
First Posted (Estimate)
December 7, 2010
Study Record Updates
Last Update Posted (Estimate)
June 1, 2012
Last Update Submitted That Met QC Criteria
May 31, 2012
Last Verified
May 1, 2012
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- 3293841
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Crystal Methamphetamine Abuse
-
Clear Scientific, Inc.National Institute on Drug Abuse (NIDA)RecruitingMethamphetamine Abuse | Methamphetamine Disorders | Methamphetamine IntoxicationUnited States
-
Centre for Addiction and Mental HealthNot yet recruitingMethamphetamine-dependence | Methamphetamine AbuseCanada
-
InterveXion Therapeutics, LLCNational Institute on Drug Abuse (NIDA)TerminatedMethamphetamine-dependence | Methamphetamine AbuseUnited States
-
University of KentuckyNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Dependence | Methamphetamine AbuseUnited States
-
University of California, Los AngelesNational Institute on Drug Abuse (NIDA)TerminatedMethamphetamine Dependence | Methamphetamine AbuseUnited States
-
University of CincinnatiNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Dependence | Methamphetamine AbuseUnited States, Canada
-
University of KentuckyNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine Dependence | Methamphetamine AbuseUnited States
-
National Institute on Drug Abuse (NIDA)RecruitingMethamphetamine-dependence | Methamphetamine AbuseUnited States
-
InterveXion Therapeutics, LLCNational Institute on Drug Abuse (NIDA)CompletedMethamphetamine-dependence | Methamphetamine AbuseUnited States
-
Laureate Institute for Brain Research, Inc.National Institute of General Medical Sciences (NIGMS)RecruitingMethamphetamine AbuseUnited States
Clinical Trials on Information, Motivation, Behavioral skills change approach to sexual risk reduction
-
The Miriam HospitalNational Heart, Lung, and Blood Institute (NHLBI)Active, not recruiting